In that study, the Aurora-B-selective compound barasertib reduced the viability of MYCN-amplified, TP53-wild-type neuroblastoma cell lines at low nanomolar potency, as well as causing tumour regression in vivo, similarly in MYCN-amplified/TP53-wild-type neuroblastoma xenografts [204]. The gene discussed is MYCN; the disease is neuroblastoma.